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A balanced interaction between dopaminergic and
cholinergic signaling in the striatum is critical to
goal-directed behavior. But how this interaction
modulates corticostriatal synaptic plasticity underly-
ing learned actions remains unclear—particularly in
direct-pathway spiny projection neurons (dSPNs).
Our studies show that in dSPNs, endogenous cholin-
ergic signaling through M4 muscarinic receptors
(M4Rs) promoted long-term depression of cortico-
striatal glutamatergic synapses, by suppressing re-
gulator of G protein signaling type 4 (RGS4) activity,
and blocked D1 dopamine receptor dependent long-
term potentiation (LTP). Furthermore, in a mouse
model of L-3,4-dihydroxyphenylalanine (L-DOPA)-
induced dyskinesia (LID) in Parkinson’s disease (PD),
boostingM4R signalingwith positive allostericmodu-
lator (PAM) blocked aberrant LTP in dSPNs, enabled
LTP reversal, and attenuated dyskinetic behaviors.
An M4R PAM also was effective in a primate LID
model. Taken together, these studies identify an
important signaling pathway controlling striatal syn-
aptic plasticity and point to a novel pharmacological
strategy for alleviating LID in PD patients.
INTRODUCTION
The striatum is a key component of the basal ganglia circuitry
controlling action selection and habit learning (Gerfen and
Surmeier, 2011; Maia and Frank, 2011; Yin and Knowlton,762 Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc.2006). It is widely assumed that activity-dependent alterations
in the strength of corticostriatal glutamatergic synapses formed
on principal spiny projection neurons (SPNs) underlie striatal
learning (Lerner and Kreitzer, 2011; Wickens et al., 2003). Not
only are these synapses important for normal learning, their dys-
regulation has been implicated in a number of psychomotor dis-
eases, including Parkinson’s disease (PD) (Gerfen and Surmeier,
2011; Kreitzer and Malenka, 2007; Shen et al., 2008).
One of themost important modulators of corticostriatal synap-
ses is dopamine (DA) (Calabresi et al., 2007; Gerfen and Surme-
ier, 2011; Kreitzer and Malenka, 2007; Lovinger, 2010; Shen
et al., 2008). By virtue of their differential expression of G pro-
tein-linked DA receptors, striatal indirect-pathway SPNs (iSPNs)
and direct-pathway SPNs (dSPNs) respond to DA in contrasting
ways. In D2 DA receptor (D2R)-expressing iSPNs, DA promotes
the induction of Hebbian long-term depression (LTD) at cortico-
striatal synapses and opposes A2a adenosine receptor (A2aR)-
mediated induction of long-term potentiation (LTP) (Shen et al.,
2008). This is accomplished by bidirectionally regulating adenylyl
cyclase (AC) through Gi-coupled D2Rs and Golf-coupled A2aRs
(Augustin et al., 2014; Higley and Sabatini, 2010; Lerner et al.,
2010).
In dSPNs, Golf-coupled D1 DA receptors (D1Rs) are necessary
for the induction of LTP. D1R signaling also disrupts the induc-
tion of Hebbian LTD (Fino et al., 2010; Pawlak and Kerr, 2008;
Shen et al., 2008; Wu et al., 2015; Yagishita et al., 2014). But it
is unclear whether there is a receptor that is homologous to
the D2R in dSPNs that promotes LTD and opposes LTP induc-
tion. One candidate for this role is the Gi-coupled M4muscarinic
receptor (M4R). The M4R is the most abundant striatal musca-
rinic receptor and it is preferentially expressed in dSPNs where
it is clustered near axospinous glutamatergic synapses (Bernard
et al., 1992; Hersch et al., 1994). Giant cholinergic interneurons
(ChIs) have dense terminal fields that overlap those of DA
Figure 1. M4RSignalingPromotes Induction
of LTD at dSPN Glutamatergic Synapses
(A) The experimental configuration.
(B) The post-pre theta-burst pairing protocol for
induction of LTD.
(C) LTD was not induced by a post-pre timing
pairing in dSPNs. Plots show EPSP amplitude
(amp) and membrane input resistance (Ri) as a
function of time. The dashed line represents the
average EPSP amplitude before induction.
STDP pairing is indicated by the vertical bar. Filled
symbols specify the averages of 12 trials (±SEM).
The averaged EPSP traces before and after in-
duction are shown at the top. Scale bars, 2 mV 3
80 ms.
(D) In the presence of D1R antagonist SCH23390
(3 mM), a post-pre timing pairing revealed LTD; the
LTDwas disruptedby addition of the selectiveM4R
antagonist MT3 (100 nM). Data are represented as
mean ± SEM. Plot of the average EPSP amplitudes
as a function of time.
(E) With 20 repetitions of the pairing protocol, bath
perfusion of VU10010 did not lead to LTD induc-
tion. However, when the number of repetitions was
increased to 60 in the presence of the M4R PAM,
LTD induction was robust. Plot of the average
EPSP amplitudes as a function of time is shown. Error bars represent ± SEM.
(F) In D1-Cre mice, post-pre pairing led to LTD when VU10010 (5 mM) was bath applied; but the same protocol had no effect on the induction of LTD in D1-M4-KO
mice. Data are shown as mean ± SEM. Plot of the average EPSP amplitudes as a function of time (see also Figures S1 and S2).neurons, allowingM4R suppression of D1R signaling through AC
(Jeon et al., 2010; Sa´nchez et al., 2009). Nevertheless, the role of
M4Rs in regulating synaptic plasticity in dSPNs has not been
determined.
Pinning down the role of M4Rs in modulating corticostriatal
synaptic plasticity could have translational implications. One of
the unmet clinical needs for PD patients is a strategy for reducing
L-DOPA-induced dyskinesia (LID). L-DOPA treatment is a main-
stay for early- and mid-stage PD patients. Although it is initially
effective in alleviating symptoms, as the disease progresses,
L-DOPA becomes less effective and the dose required to
achieve symptomatic benefit rises. In most patients, high doses
of L-DOPA produce unwanted dyskinetic movements. Although
it is unlikely that dysregulation of dSPN corticostriatal synapses
is solely responsible for LIDs, many lines of evidence suggest
that aberrant D1R-dependent synaptic plasticity is a major
factor (Feyder et al., 2011; Jenner, 2008; Picconi et al., 2003).
In particular, it is thought that repeated L-DOPA treatment
abnormally increases D1R signaling, leading to pathological
LTP of corticostriatal synapses and inappropriately timed or
scaled dSPN activity (Picconi et al., 2003). Antagonizing D1Rs
is not a viable therapeutic strategy because it diminishes the
symptomatic benefit of L-DOPA treatment. Hence, identifying
an alternative means of normalizing D1R signaling could provide
relief from LID.
The goal of the studies described here was to test two linked
hypotheses. The first hypothesis was that dSPN M4Rs sup-
pressed Hebbian LTP induction through Gi-coupled inhibition
of AC and promoted LTD by diminishing regulator of G protein
signaling type 4 (RGS4) activity (Blazer et al., 2015; Lerner and
Kreitzer, 2012). The second hypothesis was that boosting M4Rsignaling would diminish the deficits in dSPN synaptic plasticity
and aberrant behavior in models of LID. The data presented
confirm both hypotheses.
RESULTS
M4R Signaling Was Necessary for LTD at dSPN
Glutamatergic Synapses
To determine whether M4Rs were modulating synaptic plas-
ticity, we used a spike-timing-dependent plasticity (STDP) para-
digm (Fino et al., 2010; Nazzaro et al., 2012; Pawlak and Kerr,
2008; Shen et al., 2008; Shindou et al., 2011; Wu et al., 2015;
Yagishita et al., 2014). SPNswere interrogated in ex vivo cortico-
striatal parasagittal brain slices fromDrd1a orDrd2 bacterial arti-
ficial chromosome (BAC) transgenic mice in which dSPNs and
iSPNs (respectively) expressed tdTomato or enhanced GFP
(eGFP), allowing them to be reliably sampled. Once identified,
neurons were monitored and controlled with perforated-patch
recording, unless otherwise stated (Figure 1A). Synaptic plas-
ticity was induced by pairing local stimulation of glutamatergic
afferent fibers with postsynaptic spikes evoked by short bursts
of intracellular current injection that were repeated at 5 Hz (Fig-
ures 1B and 5A). As showed in earlier work with dSPNs, pairing
postsynaptic spiking with a trailing presynaptic volley failed to
change excitatory postsynaptic potential (EPSP) amplitudes
(Figure 1C). However, the same protocol led to LTD in dSPNs
when D1Rs were antagonized by bath application of the D1R
antagonist SCH23390 (3 mM; n = 7; p < 0.05, Wilcoxon signed
rank test) (Figure 1D). The engagement of D1Rs in our ex-
perimental paradigm likely stems from the fact that local ele-
ctrical stimulation activates not only glutamatergic fibers, butNeuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc. 763
Figure 2. Elevating Endogenous ChI Activity with DREADD hM3D(q)
Enhances dSPN LTD Induction
(A) ChAT Cre-dependent expression of DREADD hM3D(q) in ChIs (mCitrine
reporter) in D1tdTomato BAC mouse.
(B) DREADD cognate ligand CNO (10 mM) increased ChI spontaneous
discharge rate recorded in cell-attached patches.
(C) Box plot summary of the increase of discharge rate of ChIs. Box plot boxes
indicate upper and lower quartiles; whiskers specify upper and lower 90%.
**p < 0.01.
(D and E) Enhancing local cholinergic signaling promoted the induction of LTD
at neighboring dSPN glutamatergic synapses. Plot of the average EPSP am-
plitudes as a function of time is shown. Error bars indicate SEM. The LTD was
disrupted by (D) the M4R antagonist MT3 (100 nM) or (E) the CB1R antagonist
AM251 (2 mM). Solid line (average) and gray shadow (±SEM) are control LTD
from (D) for reference.dopaminergic fibers as well (Threlfell et al., 2012). Regardless,
these results confirm that D1R signaling disrupts the induction
of LTD in dSPNs (Shen et al., 2008; Wu et al., 2015).
Although these experiments establish the ability of D1Rs to
disrupt LTD induction in dSPNs, they do not make it clear
whether activation of other G protein-coupled receptors is
necessary for induction. Previous work has shown that type 5
metabotropic glutamate receptors (mGluR5) are critical for
STDP LTD (Fino et al., 2010; Nazzaro et al., 2012; Shen et al.,
2008), but are there others? As outlined above, M4Rs might
play a role in dSPNs that is analogous to that of D2Rs in iSPNs,
which are necessary for LTD induction (Kreitzer and Malenka,
2007; Lerner and Kreitzer, 2012). To test this possibility, we
bath applied the selective M4R antagonist—muscarinic toxin 3
(MT3, 100 nM)—(along with the D1R antagonist SCH23390) prior
to stimulation. MT3 blocked induction of LTD (SCH23390 n = 7;
SCH23390 + MT3 n = 6; p < 0.05, Mann-Whitney rank sum test)
(Figure 1D), establishing the necessity of M4R stimulation for
dSPN STDP LTD, even when D1Rs were blocked. In contrast,764 Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc.M4R antagonism with MT3 had no effect on STDP LTD in iSPNs
(Figure S1).
If M4R signaling was robust, could it overcome concomitant
D1R signaling? To amplify appropriately timed endogenous
cholinergic signaling in the STDP protocol, we used an M4R-
positive allosteric modulator (PAM); PAMs do not stimulate re-
ceptors directly but enhance their response to endogenous
acetylcholine (ACh) (Brady et al., 2008; Shirey et al., 2008). In
the absence of a D1R antagonist, 20 repetitions of the pairing
protocol did not lead to LTD induction in the presence of the
M4R PAM VU10010 (5 mM) (n = 7; p > 0.05, Wilcoxon test) (Fig-
ure 1E). This repetition number is adequate for LTD induction in
iSPNs (Shen et al., 2008). However, when the number of repeti-
tions was increased to 60 (matching the number of afferent
volleys used in the LTP induction protocol, see Experimental
Procedures) in the presence of the M4R PAM, LTD induction
was robust in dSPNs (n = 6; p < 0.05, Wilcoxon test) (Figure 1E).
Consistent with the work using conventional plasticity protocol
(Calabresi et al., 2007; Lovinger, 2010), blocking N-methyl-D-
aspartate receptors (NMDARs) with APV (50 mM) had no effect
on the M4R-mediated LTD induction (n = 6; p < 0.05, Wilcoxon
test) (Figure S2A). These results demonstrate that enhancing
M4R signaling can lead to LTD induction even when D1Rs are
activated.
Although the predominant expression site of striatal M4Rs is
dSPNs, they are also positioned at other sites in the striatum
where they are poised to exert concerted effects. For example,
activation of M4Rs on corticostriatal terminals can diminish
glutamate release (Higley et al., 2009; Pancani et al., 2014). To
determine whether postsynaptic M4Rs mediate the timing-
dependent induction of LTD in dSPNs, we employed Cre/loxP-
based strategy to generate mutant mice that lack M4Rs only in
dSPNs (D1-M4-knockout [KO] mice) (Jeon et al., 2010). These
mice, which lacked M4Rs in dSPNs, and D1-Cre mice were
then injected with an adeno-associated virus (AAV) containing
a double-floxed inverted tdTomato transgene, allowing dSPNs
to be optically identified. Preceding synaptic stimulation
(–10 ms) with a short burst of postsynaptic spikes resulted in
STDP LTD in D1-Cre mice when VU10010 (5 mM) was bath
applied, as described above. But the same protocol failed to
alter EPSP amplitudes in D1-M4-KO mice (D1-Cre n = 6; D1-
M4-KO n = 6; p < 0.05, Mann-Whitney test) (Figure 1F). These re-
sults demonstrate that postsynaptic, but not presynaptic, M4Rs
promote the induction of LTD in dSPNs.
One of the potential limitations of these experiments is that in
an ex vivo slice preparation at 30C–31C, spontaneous ChI ac-
tivity is low. One way to compensate for lower than normal
cholinergic signaling is to use designer receptors exclusively
activated by designer drugs (DREADDs) to selectively increase
ChI discharge rate (Rogan and Roth, 2011). To this end, bi-trans-
genic mice expressing tdTomato in dSPNs and Cre-recombi-
nase under control of the choline acetyltransferase (ChAT) regu-
latory elements received striatal injections of an AAV containing
an hM3D(q) expression construct with an upstream floxed STOP
cassette; this STOP cassette is effectively excised by Cre-re-
combinase leading to DREADD expression (Figure 2A). When
activated by its cognate ligand clozapine-N-oxide (CNO), the
hM3D(q) receptor activates phospholipase C (PLC) signaling
Figure 3. M4R Regulates dSPN LTD through RGS4 Signaling
(A) LTDwas inducedwith fewer (20) repetitions of the post-pre pairing protocol
by co-application of the ACh esterase inhibitor physostigmine (PHY; 10 mM)
and VU10010 (VU; 5 mM). The induction was blunted in the presence of the
M4R antagonist MT3 (100 nM). Plot of normalized EPSP amplitude as a
function of time. The dashed line represents the average of EPSP amplitude
before induction. STDP induction is indicated by the vertical bar.
(B) Intracellular application of the RGS4 specific inhibitor CCG203769 (CCG;
10 mM) promoted the induction of LTD, even in the absence of the M4R PAM
VU10010. The LTD was disrupted by the mGluR5 antagonist MPEP (10 mM).
(C) Moreover, CCG enhanced LTD induction even in the presence of M4R
antagonist. Solid line (average) and gray shadow (±SEM) are the LTD antag-
onism byMT3 from (A) for reference. Plot of the average EPSP amplitudes as a
function of time is shown. Error bars indicate SEM.
(D) Schematic showing the proposed signaling pathway through which M4Rs
and D1Rs modulate the induction of dSPN LTD; AEA, anandamide (see also
Figure S2).(Rogan and Roth, 2011). The PLC-dependent depletion of a
membrane lipid phosphotidylinositol 4,5-bisphosphate (PIP2)
decreases KCNQ (Kv7) and Kir2 K+ channel opening, enhancing
action potential generation (Rogan and Roth, 2011). Five to six
weeks after AAV injection, brain slices were made from these
mice; in these slices, bath perfusion of CNO (10 mM) increased
the discharge rate of ChIs into the physiological range (control
median = 1.1 Hz [range: 0.7–2.2]; CNO median = 6.3 Hz [range:
4.2–7.8]; n = 6; p < 0.01, Mann-Whitney test) (Figures 2B and 2C).
With elevated ChI activity, preceding synaptic stimulation with
a short burst of postsynaptic spikes led to a robust LTD in adja-
cent dSPNs (n = 6; p < 0.05, Wilcoxon test) (Figure 2D). As ex-
pected, bath application of the M4R-selective antagonist MT3
blunted the LTD induction (CNO n = 6; CNO + MT3 n = 5; p <
0.05, Mann-Whitney test) (Figure 2D). Moreover, this STDP
LTD was dependent upon endocannabinoid (eCB) CB1 recep-
tors (CB1Rs; AM251, 2 mM; CNO n = 6; CNO + AM251 n = 6;p < 0.05, Mann-Whitney test) (Figure 2E), suggesting a mecha-
nistic parallel to D2R-dependent LTD-induced in iSPNs (Kreitzer
and Malenka, 2007; Lerner and Kreitzer, 2012; Lovinger, 2010;
Shen et al., 2008; Wu et al., 2015).
Another way to counteract a weak cholinergic signaling is to
lower ACh esterase activity in our ex vivo slice preparation with
the specific inhibitor physostigmine (PHY, 10 mM) together with
VU10010 (5 mM). This combination produced robust LTD induc-
tion with only 20 repetitions of the pairing protocol (n = 6; p <
0.05, Wilcoxon test) (Figure 3A). As anticipated, antagonizing
M4Rs with MT3 (100 nM) disrupted the induction of LTD (VU +
PHY n = 6; VU + PHY + MT3 n = 6; p < 0.05, Mann-Whitney
test) (Figure 3A). However, blocking D2Rs with sulpiride
(10 mM) had no effect on the induction of dSPN LTD (Figure S2B)
(Shen et al., 2008; Wu et al., 2015).
M4Rs Regulate dSPN LTD Induction through RGS4
The results thus far indicate that M4Rs are necessary participant
in postsynaptic generation of eCBs that act at presynaptic
CB1Rs to produce a sustained reduction in glutamate release,
much like D2Rs in iSPNs (Kreitzer and Malenka, 2007). D2Rs
diminish protein kinase A (PKA) phosphorylation of RGS4, which
negatively modulates the ability of mGluR5 to activate Gaq and
PLC isoforms coupled to the generation of eCBs (Lerner and
Kreitzer, 2012). To test whether RGS4 is involved in regulation
of the induction of dSPN LTD by M4Rs, we used a newly devel-
oped, selective RGS4 antagonist CCG203769 (Blazer et al.,
2015). In this set of experiments, CCG203769 was applied
through the patch pipette in whole-cell mode to restrict its
action to the postsynaptic neuron. Intracellular application of
CCG203769 (10 mM) enhanced induction of LTD during repeated
pairing of postsynaptic spikes with presynaptic stimulation
10 ms later, even without boosting M4R stimulation with
VU10010. This suggests that acute inhibition of RGS4 signaling
dissociates LTD induction from M4Rs (CCG203769 n = 6; p <
0.05, Wilcoxon test) (Figure 3B). Indeed, when RGS4 signaling
was blocked by CCG203769, antagonizing M4Rs had no effect
on dSPN LTD (VU + PHY + MT3 n = 6; VU + PHY + MT3 +
CCG203769 n = 7; p < 0.05, Mann-Whitney test) (Figures 3C
and 3D). However, LTD induction still required mGluR5 stimula-
tion, as blocking mGluR5 with MPEP (10 mM) prevented the LTD
induction (CCG203769 n = 6; CCG203769 + MPEP n = 6; p <
0.05, Mann-Whitney test) (Figure 3B).
M4Rs Inhibited NMDAR-Mediated Synaptic Currents
and Ca2+ Transients
In iSPNs, D2R signaling is not only necessary for LTD induction,
but also prevents the induction of LTP (Higley and Sabatini,
2010; Shen et al., 2008). In part, this modulation is likely medi-
ated by suppression of NMDAR-mediated Ca2+ entry (Higley
and Sabatini, 2010). M4Rs might also negatively modulate
NMDARs. To test this hypothesis, we filled dSPNs with the
Ca2+-insensitive red fluorophore Alexa Fluor 568 and the Ca2+-
sensitive green fluorophore Fluo-5F to allow visualization of
dendritic spines and simultaneous monitoring of NMDAR-medi-
ated changes in intracellular Ca2+ concentration (Figure 4A).
In these cells, glutamate was uncaged at spine heads in the
presence of a-amino-3-hydroxy-5-methyl-4-isoxazole propionicNeuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc. 765
Figure 4. M4R Activation on dSPNs Inhibits
Postsynaptic NMDAR-Mediated Ca2+ Tran-
sients and Currents
(A) Low (left)- and high (right)-magnification
maximum-intensity projections of a dSPN filled
with Alexa Fluor 568. Spine was stimulated with
1 ms uncaging pulse of 720–725 nm light.
(B) In the presence of the D1R agonist SKF81297
(3 mM), average NMDAR Ca2+ transients in a distal
dSPN spine induced by a single glutamate un-
caging pulse were reduced by the M4R PAM
VU10010 (VU; 5 mM). Solid lines are averages
across multiple spines and the shaded areas
represent the mean ± SEM. Mus, muscarine.
(C) Box plot summary of modulation of NMDAR-
mediated Ca2+ transients. SKF, SKF81297.
(D) Addition of VU 10010 (5 mM) suppressed
NMDAR-mediated uEPSC currents triggered by
uncaging pulses of 500 Hz to five distal spines.
Solid lines are averages across multiple spines
and the shaded areas represent the mean ± SEM.
(E) NMDAR-mediated EPSCs recorded from
dSPNs in the presence of muscarine (3 mM; top
traces) and muscarine + VU10010 (5 mM; bottom
traces). EPSCs are averages of ten consecutive
trials.
(F) Left: time course of EPSC amplitude from the
experiment shown in (E). Muscarine and VU10010were applied during the time indicated by the horizontal bars. Right: box plot sum ofM4R-mediatedmodulation
of NMDAR currents. All box plot boxes indicate top and bottom quartiles; whiskers specify top and bottom 90%. *p < 0.05 (see also Figure S3).acid receptor (AMPAR) antagonist NBQX (10 mM) and the
muscarinic receptor agonist muscarine (3 mM), while monitoring
the postsynaptic response with and without the M4R PAM
VU10010 (5 mM) (Figure 4B). NMDAR-mediated Ca2+ transients
were not altered by the M4R PAM in this situation (n = 10; p >
0.05, Wilcoxon test) (Figure S3). One interpretation of this nega-
tive result is that M4R signaling only affects NMDARs that have
been positively modulated by D1R stimulation; D1R-mediated
activation of PKA increases phosphorylation of the NMDAR
NR2B subunit, enhancing receptor currents (Murphy et al.,
2014). To test this possibility, we applied the D1R agonist
SKF81297 (3 mM) and then co-applied muscarine and the M4R
PAM. In this situation, M4R signaling decreased NMDAR-medi-
ated Ca2+ transients by 40% (n = 12; p < 0.05, Wilcoxon test)
(Figures 4B and 4C), in agreement with previous studies (Higley
and Sabatini, 2010).
In some neurons, it has been found that Ca2+ permeability—
but not total transmembrane current—is enhanced by phos-
phorylation of NMDARs (Higley and Sabatini, 2010). In other
neurons, both Ca2+ permeability and total current are modulated
in parallel (Murphy et al., 2014). To determine the situation in
dSPNs, we examined the effect of muscarine and VU10010 on
NMDAR-mediated excitatory postsynaptic currents (EPSCs)
evoked by uncaging glutamate on spine heads (uEPSCs) in the
presence of SKF81297. M4R signaling significantly reduced
the amplitude of these postsynaptic NMDAR-mediated uEPSCs
(n = 8; p < 0.05, Wilcoxon test) (Figure 4D). In addition, muscarine
(3 mM) reduced the amplitudes of NMDAR-mediated EPSCs
evoked by local electrical stimulation and this modulation was
augmented by VU10010 (5 mM) (muscarine n = 10, muscarine +
VU10010 n = 10; p < 0.05, Wilcoxon test) (Figures 4E and 4F).766 Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc.Taken together, these data show that dSPNM4R activation sup-
presses both total current and Ca2+ influx at spine NMDARs.
M4R Signaling Attenuated LTP Induction in dSPNs
As shown previously (Pawlak and Kerr, 2008; Shen et al., 2008;
Yagishita et al., 2014), pairing a presynaptic spike with a trailing
postsynaptic spike induced a potent LTP in dSPNs (Figures 5A–
5C). This form of STDP LTP is dependent upon D1R signaling
and Ca2+ entry through NMDARs (Pawlak and Kerr, 2008;
Shen et al., 2008; Yagishita et al., 2014). One of the downstream
targets of D1R and NMDAR signaling that has been implicated in
LTP induction is extracellular signal-regulated kinase (ERK) (Pas-
coli et al., 2012; Plotkin et al., 2014). As expected from previous
work, inhibition of ERKwith themitogen-activated protein kinase
kinase or MEK inhibitor U0126 (10 mM) disrupted STDP LTP in
dSPNs (control n = 8; U0126 n = 5; p < 0.05, Mann-Whitney
test) (Figure 5C). Given its ability to antagonize D1R signaling
and Ca2+ entry through NMDARs, M4R stimulation should
impede the induction of LTP in dSPNs. As predicted, boosting
M4R signaling with the M4R PAM disrupted STDP LTP induction
(control n = 8; VU10010 n = 6; p < 0.05, Mann-Whitney test)
(Figure 5D).
Shortly after LTP induction, synaptic strength is unstable. Dur-
ing this time, low-frequency afferent fiber stimulation (LFS;
2–5 Hz, 10 min) can reverse LTP; this reversal is called depoten-
tiation (Otmakhova and Lisman, 1998). Depotentiation is trig-
gered by Ca2+/calmodulin-mediated activation of protein phos-
phatase 2B (PP2B, or calcineurin); PP2B dephosphorylates
DA and cAMP-regulated phosphoprotein of 32 kDa (DARPP-
32), resulting in the dis-inhibition of protein phosphatase 1
(PP1) (Otmakhova and Lisman, 1998; Picconi et al., 2003); PP1
Figure 5. M4R Stimulation Blunts LTP In-
duction at dSPN Synapses and Enables De-
potentiation
(A) The pre-post theta-burst pairing protocol for
induction of LTP.
(B) LTPwas induced by a pre-post timing pairing in
dSPNs. Plots show EPSP amplitude (amp) and
membrane input resistance (Ri) as a function of
time. The dashed line represents the average
EPSP amplitude before induction. The vertical bar
indicates STDP induction. Filled symbols specify
the averages of 12 trials (±SEM). The averaged
EPSP traces before and after induction are shown
at the top. Scale bars, 4 mV 3 80 ms.
(C) LTP induction was disrupted by MEK inhibitor
U0126 (10 mM). Plot of the average EPSP ampli-
tudes as a function of time is shown.
(D) LTP induction was also blocked by the M4R
PAMVU10010 (5 mM). Solid line (average) and gray
shadow (±SEM) are control LTP from (C) for
reference.
(E) Synaptic depotentiation was not induced by
LFS (@2 Hz for 10min) during the time indicated by
the horizontal bar. However, pre-perfusion of a
D1R antagonist SCH23390 (3 mM) facilitated de-
potentiation.
(F) VU10010 (5 mM) also promoted the reversal of
established LTP. Solid line (average) and gray
shadow (±SEM) are control from (E) for reference.
Error bars represent SEM.dephosphorylates GluA subunits recently trafficked into the
synaptic membrane during LTP expression, leading to their
removal (Lee et al., 2000). The serine residue on DARPP-32 tar-
geted by PP2B is phosphorylated by PKA. So, in principle,
D1R stimulation of PKA should prevent depotentiation (Otma-
khova and Lisman, 1998). Consistent with this inference, 2 Hz
intrastriatal stimulation, which also activates the axons of
dopaminergic fibers, did not depotentiate dSPN glutamatergic
synapses (n = 7; p > 0.05, Wilcoxon test) (Figure 5E). However,
in the presence of the D1R antagonist SCH23390 (3 mM), the
same protocol depotentiated glutamatergic EPSPs (control n =
7; SCH23390 n = 6; p < 0.05, Mann-Whitney test) (Figure 5E).
More importantly within the context of the current study, depot-
entiation also was achieved by addition of the M4R PAM
VU10010 (5 mM; control n = 7; VU10010 n = 6; p < 0.05, Mann-
Whitney test) (Figure 5F), consistent with previous work suggest-
ing that muscarinic receptor activation promotes depotentiation
(Picconi et al., 2006).
Aberrant Synaptic Plasticity in dSPNs Was Corrected by
an M4R PAM
Four to six weeks after a 6-hydroxydopamine (6-OHDA) lesion of
the dopaminergic innervation to the striatum, conventional forms
of striatal synapticplasticity are lost (Picconi et al., 2003). Although
present shortly after lesioning (Shen et al., 2008), STDP also was
lost at longer survival times. In brain slices from D1-tdTomato
and D2-eGFP BAC mice that had unilateral 6-OHDA lesions
3–4 weeks previously (Figure 6A), repeated pairing of synaptic
stimulation with a postsynaptic spike 10 ms later did not change
EPSP amplitude in dSPNs (n = 6; p > 0.05, Wilcoxon test) (Fig-
ure 6B) or iSPNs (n = 5; p > 0.05, Wilcoxon test) (Figure S4).Elevating striatal DA in lesioned rodents by systemic adminis-
tration of the DA precursor, L-DOPA, restores some forms of
striatal synaptic plasticity (Belujon et al., 2010; Picconi et al.,
2003; Thiele et al., 2014). However, repeated L-DOPA treatment
of parkinsonian rodents results in abnormal involuntary move-
ments (AIMs), mimicking human LID (Cenci, 2007). In the rat
LID model, high-frequency stimulation (HFS) of the striatum in-
duces LTP at SPN glutamatergic synapses, but depotentiation
of these synapses is disrupted (Picconi et al., 2003). However,
it is unclear whether either of these effects generalizes to
STDP and whether these effects are specific to dSPNs or iSPNs.
To answer this question, we generated a mouse model of LID in
which dSPNs and iSPNs were labeled (see Experimental Proce-
dures). One hour after the last injection of L-DOPA, mice were
sacrificed and ex vivo brain slices were prepared for patch-
clamping recordings, two-photon laser-scanning microscopy,
and glutamate uncaging. In dSPNs from L-DOPA-treated mice,
the standard pre-post STDP induction protocol led to a robust
LTP (n = 7; p < 0.05, Wilcoxon test) (Figure 6B). As in tissue
from untreated mice, blocking ERK activity with U0126 pre-
vented LTP induction—arguing that the plasticity was induced
by the same mechanisms as in untreated mice (dyskinetic n =
7; dyskinetic + U0126 n = 5; p < 0.05, Mann-Whitney test) (Fig-
ure 6C). However, in iSPNs from LID mice, the same STDP
protocol induced LTD (6-OHDA n = 5; L-DOPA n = 6; p < 0.05,
Mann-Whitney test) (Figure S4). These results demonstrate
that synaptic plasticity in SPNs following L-DOPA treatment
is not grossly abnormal and continues to be governed by SPN
subtype. Moreover, enhancing M4R signaling with VU10010
blocked the induction of STDP LTP in dSPNs from LID mice
(dyskinetic n = 7; dyskinetic + VU10010 n = 6; p < 0.05,Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc. 767
Figure 6. M4R PAM Attenuates Synaptic
Plasticity Deficits in dSPNs from LID Mice
(A) Light microscopic image of a coronal section
illustrating the loss of immunoreactivity for tyro-
sine hydroxylase (TH) after unilateralMFB 6-OHDA
lesioning. CPu, caudate-putamen.
(B) LTP induction was lost in prolonged 6-OHDA-
lesioned animals. Shortly after the last injection of
L-DOPA, LTP was recovered in dSPNs. Plot of
average EPSP amplitude as a function of time.
(C) The LTP was disrupted by U0126 (10 mM) or
VU10010 (5 mM). Solid line (average) and gray
shadow (±SEM) are LTP from (B) for reference.
(D) Low (left)- and high (right)-magnification
maximum-intensity projections of a dSPN filled
with Alexa Fluor 568.
(E) NMDAR-mediated Ca2+ transients were
decreased by addition of VU10010 (VU; 5 mM) in
dSPNs from LID mice. Solid lines are averages
across multiple spines and the shaded areas
represent the mean ± SEM. *p < 0.05. Mus,
muscarine.
(F) In dyskinetic animals, synaptic depotentiation
was lost and restored by bath application of
SCH23390 (SCH; 3 mM) or VU10010 (5 mM). Hori-
zontal bar indicates LFS (2 Hz, 10 min). Error bars
represent SEM. Box plot boxes specify top and
bottom quartiles; whiskers indicate top and bot-
tom 90% (see also Figure S4).Mann-Whitney test) (Figure 6C), and reduced NMDAR-mediated
Ca2+ transients (n = 10; p < 0.05, Wilcoxon test) (Figures 6D and
6E), just as in naive mice.
Was depotentiation altered in dSPNs from LID mice? As pre-
dicted by previous work (Picconi et al., 2003), intrastriatal LFS
(2 Hz, 10 min) failed to depotentiate EPSPs in dSPNs from LID
mice (n = 6; p > 0.05,Wilcoxon test) (Figure 6F). This could reflect
a deficit in the intracellular machinery underlying depotentiation
or it could simply be a consequence of sustained D1R stimula-
tion following the last L-DOPA dose. To test the latter hypothesis,
we antagonized D1Rs by bath application of SCH23390 and the
LFS protocol repeated. In this situation, glutamatergic synapses
depotentiated (dyskinetic n = 6; dyskinetic + SCH23390 n = 6;
p < 0.05, Mann-Whitney test) (Figure 6F), arguing that the depot-
entiation machinery was intact. Boosting M4R signaling with the
M4R PAM also restored depotentiation in the absence of a D1R
antagonist (dyskinetic n = 6; dyskinetic + VU10010 n = 6; p <
0.05, Mann-Whitney test) (Figure 6F).
M4R PAM Administration Reduced Dyskinetic Behavior
Aberrant striatal LTP has been hypothesized to contribute to the
development of dyskinetic behavior (Jenner, 2008; Picconi et al.,
2003). The data presented to this point demonstrate that
enhancing M4R signaling with a PAM can blunt D1R-mediated
LTP in dSPNs of LID models, both by diminishing LTP induction
and by enabling depotentiation. Thus, systemic administration of
an M4R PAM should attenuate LID-like behavior. To test this hy-
pothesis, we examined two different animal models of LID. First,
mice were unilaterally lesioned with 6-OHDA and then given in-
cremental doses of L-DOPA (1.5–6 mg kg–1, i.p.). These mice
were randomly assigned to receive treatment with either L-768 Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc.DOPA and vehicle or L-DOPA and VU0467154 (10 mg kg–1,
i.p.); VU0467154 is an M4R PAM with better pharmacokinetic
properties than VU10010. As predicted, VU0467154 significantly
attenuated peak AIM scores induced by each dose of L-DOPA
(1.5 mg kg–1: L-DOPA n = 9; L-DOPA + VU0467154 n = 9;
p < 0.05, Mann-Whitney test; 3 mg kg–1: L-DOPA n = 9; L-
DOPA + VU0467154 n = 9; p < 0.01, Mann-Whitney test; 6 mg
kg–1: L-DOPA n = 9; L-DOPA + VU0467154 n = 9; p < 0.01,
Mann-Whitney test) (Figures 7A and 7B). The reduction in dyski-
nesia scores did not occur at the expense of the anti-parkinso-
nian effects of L-DOPA, as forelimb use asymmetry (Schallert
et al., 2000) was improved by L-DOPA alone or when co-admin-
istered with VU0467154 (L-DOPA: n = 9, p < 0.01, Wilcoxon test;
L-DOPA + VU0467154: n = 9; p < 0.01, Wilcoxon test).
A separate group of L-DOPA-primed and dyskineticmicewere
challenged with L-DOPA and another M4R PAM (VU0152100),
or its vehicle, to examine the striatal induction of phosphorylated
ERK1/2 (pERK1/2) and phosphorylated histone 3 (pH3)—
neuronal markers that strongly correlated with LID severity
(Santini et al., 2009). The M4R PAM significantly reduced the
number of neurons immunoreactive for these markers in the
lateral (motor) part of the striatum (pERK1/2: L-DOPA n = 9;
L-DOPA + VU0152100 n = 9; p < 0.05; pH3: L-DOPA n = 9;
L-DOPA + VU0152100 n = 9; p < 0.05, Mann-Whitney test)
(Figure S5).
Next, four nonhuman primates were rendered parkinsonian
with repeated intravenous (i.v.) injections of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) hydrochloride (Be´zard et al.,
2003) and then subjected to a chronic L-DOPA treatment regimen
that reliably induces dyskinesia (Ko et al., 2014). Because
VU0467154 has limited potency at primate M4Rs, VU0476406,
Figure 7. M4R PAMs Alleviate Dyskinetic Behaviors
(A) Plot of sum of mouse AIM scores (n = 9, mean ± SEM) as a function of time.
Systemic treatment with VU0467154 (10mg kg–1) produced a significant overall
reduction in AIM scores (time: p < 0.001; group: p < 0.01; interaction: p < 0.01;
repeated-measure two-way ANOVA followed by Bonferroni’s post test).
(B) Box plot summation shows that VU0467154 attenuates LID behaviors over
a range of L-DOPA doses. Mice were treated with ascending doses of L-DOPA
combined with either the M4R PAM or its vehicle (n = 9 per group). VU0467154
was effective on each of the three L-DOPA doses (1.5, 3, or 6 mg kg–1) indi-
cated by horizontal bars. Box plot boxes indicate top and bottom quartiles;
whiskers specify top and bottom 90%. *p < 0.05; **p < 0.01.
(C) Plot of sum of primate dyskinesia scores (median) as a function of time (Fr =
11.64, n = 4; p < 0.01, Friedman’s test).
(D) Box plot summary of antidyskinetic effects of VU0476406 (1, 3, or
10 mg kg–1) or amantadine (20 mg kg–1). Systemic administration of
VU0476406 (10 mg kg–1) or amantadine (20 mg kg–1) ameliorates dyskinesia
scores. *p < 0.05.a novel VU0467154 analog with improved potency (Conn et al.,
2014), was used in these experiments. The NMDAR antagonist
amantadine (20 mg kg–1, i.v.), which is used to treat dyskinesia
in PD patients (Metman et al., 1999), was used as a positive con-
trol. Vehicle, VU0476406 (1, 3, and 10 mg kg–1), or amantadine
was administered together with L-DOPA in a within-subject
design (see Experimental Procedures). As anticipated, amanta-
dine blunted dyskinetic behaviors (n = 4; p < 0.05, Friedman’s
nonparametric repeated-measure one-way ANOVA followed by
Dunn’s post test) (Figures 7C and 7D) (Ko et al., 2014).
VU0476406 at its highest concentration (10 mg kg–1), like aman-
tadine, significantly reduced LID (n = 4; p < 0.05, Friedman’s test
andDunn’s test) (Figures 7C and 7D) and did not compromise the
therapeutic effect of L-DOPA (n = 4; p > 0.05, Friedman’s test and
Dunn’s test) (Figure S6).
DISCUSSION
There are three take-home points from the studies presented.
First, endogenous cholinergic signaling through M4Rs promotes
LTD and blunts LTP at dSPN glutamatergic synapses; in this
respect, dSPN M4Rs serve a role that is analogous to that of
iSPN D2Rs. Second, enhancing endogenous M4R signaling
with an M4R PAM mitigates the synaptic plasticity deficits in
dSPNs accompanying L-DOPA treatment. Third, systemic treat-
ment with theM4R PAMs ameliorates LID in both mouse and pri-
mate models. These findings not only provide a new insight into
the way in which DA and ACh interact to shape striatal plasticity,
they point to a novel therapy for one of the major unmet medical
needs for PD patients—a pharmacological strategy for allevi-
ating LID.
M4R Signaling Promoted LTD Induction in dSPNs
One of the fundamental unresolved questions about the striatal
circuitry is how corticostriatal glutamatergic LTD is controlled
in dSPNs. In iSPNs, the landscape is very well defined. D2Rs,
mGluR5s and L-type calcium channels are necessary partici-
pants in the postsynaptic generation of eCBs that act at presyn-
aptic glutamatergic terminals to bring about a sustained reduc-
tion in glutamate release. This is true in iSPNs, regardless of
whether a STDP or HFS protocol is used.With HFS protocols uti-
lizing macroelectrodes that directly stimulate the striatum, D2R
signaling is also necessary for LTD induction in dSPNs. But
this dependence is indirect, reflecting interneuron engagement
during induction (Tozzi et al., 2011; Wang et al., 2006).
In STDP protocols that use minimal local stimulation (MLS),
D2R signaling is not necessary for LTD induction in dSPNs
(Shen et al., 2008). In fact, a number of studies using MLS
have failed to find LTD in dSPNs (Kreitzer and Malenka, 2007;
Nazzaro et al., 2012; Shen et al., 2008). This failure is attributable
to the inadvertent stimulation of dopaminergic fibers by MLS
(Threlfell et al., 2012), as antagonismof D1Rs enables LTD induc-
tion in dSPNs with MLS (Shen et al., 2008). Postsynaptic M4R
signaling enabled MLS-evoked LTD induction, even in the(E) Proposed signaling model of L-DOPA-induced deficits in dSPN synaptic
plasticity and dyskinesia; Src, Src-family kinases; PLD, phospholipase D; AEA,
anandamide (see also Figures S5–S7).
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absence of a D1R antagonist. Enhancing M4R signaling in any of
threeways—by use of anM4RPAM, by slowing AChmetabolism
in the presence of the M4R PAM, or by increasing the activity of
ChIs with a DREADD—was sufficient to establish STDP LTD. The
effects ofM4R signaling appeared to bemediated by inhibition of
AC (Jeon et al., 2010) and deactivation of RGS4, which attenu-
ates mGluR5 signaling through Gaq (Saugstad et al., 1998); in
this regard, the role of M4R signaling in LTD is very similar to
that of D2Rs in iSPNs (Lerner and Kreitzer, 2012). Why there
was an M4R signaling requirement for LTD induction in dSPNs
in the absence of D1R signaling is not entirely clear. One possi-
bility is that there are other signalingmechanisms driving AC (and
PKA) activity in dSPNs (Yagishita et al., 2014) thatmaintain RGS4
activity.
Modulation of LTP in dSPN by M4Rs
In addition to promoting the induction of LTD, M4R signaling
blocked D1R-mediated LTP induction in dSPNs. LTP induction
in dSPNs requires co-activation of PKA and Ras-guanine nucle-
otide exchange factor 1 (Ras-GEF1), which converge upon ERK
(Cerovic et al., 2015; Shen et al., 2008; Sweatt, 2004). Our
studies suggest that M4R signaling blunts activation of both
PKA and Ras-GEF1. First, M4Rs are well-known to inhibit AC
isoforms by activating Gi proteins, limiting PKA activation (Go-
meza et al., 1999; Jeon et al., 2010). Second, M4Rs reversed
D1R-mediated enhancement of NMDAR Ca2+ currents, which
is mediated by PKA phosphorylation of serine 1166 on GluN2B
subunit (Murphy et al., 2014). This modulation should diminish
synaptically driven activation of the Ca2+/calmodulin-dependent
Ras-GEF1 anchored to the GluN2B subunit (Krapivinsky et al.,
2003). Thus, the strength of dSPN glutamatergic synapses is
reciprocally modulated by M4Rs and D1Rs.
Of perhaps as much importance to global synaptic strength in
the striatum is the ability of M4R signaling to promote LTP
reversal or depotentiation in dSPNs. LTP at SPN glutamatergic
synapses is postsynaptically expressed, resulting from AMPA
trafficking into the synapse (Plotkin et al., 2014). The ability of
M4Rs to depotentiate synapses is attributable to inhibition of
AC and deactivation of DARPP-32, resulting in dis-inhibition of
PP1 and removal of AMPARs that have been recently trafficked
into the synapse (Lee et al., 2000; Otmakhova and Lisman, 1998;
Picconi et al., 2003).
Although the basic determinants of depotentiation are widely
agreed upon, poor experimental control of key experimental var-
iables in the corticostriatal slice has led to apparent discrep-
ancies. Perhaps of greatest importance, neither macroelectrode
stimulation nor MLS allows for the selective activation of cortico-
striatal axons; both inevitably activate other axons, like dopami-
nergic and cholinergic axons coursing through the striatum, to
varying degrees. The inability of minimal local LFS to induce de-
potentiation in the absence of a D1R antagonist undoubtedly re-
flects the stronger activation of dopaminergic fibers by this form
of stimulation than white matter, macroelectrode LFS, where a
D1R antagonist is not necessary (Picconi et al., 2003). However,
macroelectrode stimulation of the white matter still activates
dopaminergic fibers, as it is capable of inducing D1R LTP (Cala-
bresi et al., 2007). This lack of control also complicates the inter-
pretation of results from the disease models. For example, our770 Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc.results argue that the failure to see depotentiation with macroe-
lectrode LFS in slices from LID models is attributable to an
enhancement of D1R stimulation by drug treatment, not a funda-
mental alteration in the mechanisms governing depotentiation.
This lack of experimental control and the cellular complexity of
the striatum might also help explain the puzzling recent work
suggesting that activation of the Ras-GEF1/ERK pathway is
necessary for depotentiation (Cerovic et al., 2015). Optogenetic
and chemogenetic approaches that allow precise control over
the circuitry being engaged during the induction of synaptic plas-
ticity should allow these apparent discrepancies to be resolved.
M4R PAM Ameliorates L-DOPA-Induced Involuntary
Movements
A key unmet medical need of the PD community is a strategy
for ameliorating LID. The hope is that a rationale therapy will
come from understanding the mechanisms responsible for LID.
Several lines of evidence suggest that aberrant D1R-dependent
potentiation of dSPN glutamatergic synapses is a central feature
of the LID pathophysiology. Our work is consistent with this
conclusion. Specifically, in tissue taken from LID mice shortly af-
ter the last L-DOPA dose, STDP LTP was readily induced in
dSPNs and did not depotentiate with LFS. However, this phe-
nomenology is attributable simply to transiently elevated striatal
DA levels after the last L-DOPA injection, rather than a funda-
mental change in plasticity signaling machinery. For example,
depotentiation was immediately restored by D1R antagonism
or M4R agonism, which is not basically different from the situa-
tion in tissue from naive mice. Moreover, LTP induction was
blocked by addition of the M4R PAM, much as in naive tissue.
What is different in L-DOPA-treated mice is the spatio-temporal
distribution of D1R stimulation. Rather than being briefly stimu-
lated by burst spiking of DA neurons, D1Rs in the LID model
are stimulated for long periods of time; this abnormally sustained
stimulation is likely to underlie both the synaptic and biochemical
signature of LID in dSPNs. The sustained elevation of extracel-
lular DA following L-DOPA administration also prevents iSPNs
from responding to patterned activity appropriately. In this state,
STDP protocols that normally induce Hebbian LTP induce LTD in
iSPNs. This cell-specific biasing of synaptic plasticity—LTP for
dSPNs and LTD for iSPNs—in the LID models is consistent
with the hyperkinetic features of LID. But more importantly,
the strength of SPN synapses should be unconstrained by
action outcomes, leading to random alterations in strength.
Randomizing synaptic strength or degrading information stored
in synaptic strength could be a cause of involuntary movements
characteristic of LID.
How might the aberrant plasticity in dSPNs be ameliorated?
Clearly, counteracting D1Rs is not a feasible therapeutic strategy
because it would diminish the symptomatic benefit of L-DOPA
treatment. By amplifying endogenous cholinergic signaling, the
M4R-PAMs disrupted STDP LTP in dSPNs and enabled previ-
ously potentiated synapses to be depotentiated. In addition,
they diminishedNMDAR-mediatedCa2+ signaling and phosphor-
ylation of ERK in dyskinetic mice—a biomarker of the dyskinetic
state (Santini et al., 2009).More importantly, systemic administra-
tion ofM4RPAMs significantly diminished dyskinetic behaviors in
both mouse and primate models following L-DOPA treatment.
This was accomplished without compromising the symptomatic
benefit of L-DOPA treatment. Although the anti-dyskinetic effects
were modest, improvements in potency and pharmacokinetics
could enhance the ability of an M4R PAM to alleviate LID. For
example, matching the brain bioavailability of the M4R-PAM to
that of dopamine, so that it effectively moderates D1R signaling
during the on-state, could improve its behavioral effects.
At first glance, our results appear to be at odds with a recent
report showing that ablating striatal ChIs after lesioning dopami-
nergic neurons, but prior to L-DOPA administration, diminishes
dyskinesia (Won et al., 2014). Although intriguing, this result is
difficult to interpret. Beyond controlling synaptic plasticity in
dSPNs, ChIs have a wide range of striatal effects through both
muscarinic and nicotinic receptor signaling (Zhou et al., 2003).
Undoubtedly, ablation of ChIs will induce striatal adaptations
that could alter the effects of dopaminergic de-innervation
and subsequent L-DOPA administration (Kaneko et al., 2000).
For example, deletion of M1 muscarinic receptors significantly
attenuates spine loss in iSPNs following dopamine depletion
(Shen et al., 2007). In mice with a normal complement of
ChIs, re-establishing iSPN axospinous connectivity following
L-DOPA administration appears to be an important factor in
the emergence of dyskinesia (Fieblinger et al., 2014). This re-
wiring might be substantially altered by ChI ablation. So
while this study does not affect our conclusions, it does suggest
that understanding the consequences of ChI ablation on the stria-
tal circuitry could identify new targets for anti-dyskinetic therapy.
In summary, M4Rs expressed by dSPNs play a central role in
the regulation of synaptic plasticity of glutamatergic synapses in
both healthy and parkinsonian states. These receptors pro-
moted LTD and blocked LTP induction; they also enabled depot-
entiation. In parkinsonian mice rendered dyskinetic by L-DOPA
treatment, an M4R-PAM blunted D1R-mediated LTP and
enabled depotentiation. In both mouse and primate models,
the dyskinetic behaviors were attenuated by systemic M4R
PAM treatment as well. These results point to a novel therapy
for one of the major unmet medical needs for PD patients—a
pharmacological strategy for alleviating LID.EXPERIMENTAL PROCEDURES
Animal use procedures were approved by the Institutional Animal Care and
Use Committees. See Supplemental Experimental Procedures for detailed
methods.
Electrophysiology
Parasagittal slices were prepared from D1-tdTomato or D2-eGFP BAC trans-
genic mice (P80–P110). Whole-cell or perforated-patch recordings from SPNs
were obtained from visually identified SPNs in the dorsolateral striatum at a
temperature of 30C–31C. EPSP/Cs were evoked by intrastriatal stimulation
with a theta glass pipette placed 80–100 mm dorsolateral of the recorded neu-
rons. Long-lasting synaptic plasticity was induced using protocols consisting
of subthreshold synaptic stimulation paired with somatically induced action
potentials (APs) at theta frequency (5 Hz). These protocols consisted of
20–60 trains of five bursts repeated at 0.1 Hz, with each burst composed of
three APs preceded with three EPSPs at 50 Hz (pre-post timing pairing, +5ms)
or three APs followed by one EPSP (post-pre timing pairing, –10ms). To ensure
induction of consistent synaptic plasticity, we depolarized postsynaptic neu-
rons to –70 mV from their typical resting membrane potentials (–85 mV) during
their induction. GABAA was blocked by the bath application of gabazine.Mouse Unilateral 6-OHDA Model and LID
Mice were injected with 6-OHDA into the medial forebrain bundle at
8–10 weeks of age. Two weeks after surgery, the degree of damage to nigros-
triatal DA neurons was assessed with a forelimb-use asymmetry test (Fig-
ure S7A) (Schallert et al., 2000). Striatal sections from a subset of mice were
stained with tyrosine hydroxylase to verify successful lesion (Figure 6A). One
day after the cylinder test, mice underwent behavioral testing for AIMs
following L-DOPA treatment as previously described (Francardo et al.,
2011). For ex vivo brain slice recording, behavioral testing occurred
every other day for a total of five test sessions. Animals received 3 and 6 mg
kg–1 L-DOPA for the first two and last three behavioral sessions, respectively.
Benserazide was co-administered to inhibit peripheral conversion of L-DOPA
to DA. AIMs (axial, limb, and orolingual movements) were rated as previously
described (Figure S7B) (Cenci and Lundblad, 2007). Physiological experiments
were performed in mice sacrificed 1 hr after the last L-DOPA administration.
For behavioral pharmacology experiments as those shown in Figure 7, treat-
ment with L-DOPA was given daily for 9 days using an incremental dose
regimen (Francardo et al., 2011); at the doses of 1.5 mg kg–1 on days 1–3,
3 mg kg–1 on days 4–6, and 6 mg kg–1 on days 7–9. Animals were randomly
allocated to receive treatment with L-DOPA and vehicle, or L-DOPA and
VU0467154, which was given at the dose of 10 mg kg–1 for all treatment.
Primate MPTP Model and LID
Primates received dailyMPTP i.v. injections until PDmotor symptomswere es-
tablished (Be´zard et al., 2003); after which twice daily L-DOPA treatment was
given. L-DOPA was administered over 4–5 months for induction of stable
dyskinesia (Be´zard et al., 2003; Ko et al., 2014). Thereafter, L-DOPA was given
twice weekly for maintaining a steady level of dyskinesia.
L-DOPA and amantadine were administered orally and the M4R PAM
VU0476406 i.v. injected. Vehicle, VU0476406, or amantadine was adminis-
tered with L-DOPA in a within-subject design. A 2-day wash-out period was
given between acute drug tests.
PD and dyskinesia were rated on the established behavioral rating scales
(Fox et al., 2012) and calculated as previously described (Be´zard et al.,
2003; Ko et al., 2014).
Viral DREADD hM3D(q) Expression and Activation
Bi-transgenic mice expressing tdTomato in dSPNs and Cre-recombinase un-
der control of the ChAT regulatory elements received striatal stereotaxic injec-
tions of an AAV (serotype 2/8) containing the hM3D(q) expression construct.
Mice were allowed to recover for 5–6 weeks before recordings.
Ca2+ Imaging and Two-Photon Laser Uncaging
dSPNs were loaded with 25 mM Alexa 568 and 300 mM Fluo 5F via the internal
recording solution. The laser-scanned images were acquired with 810 nm light
pulsed at 90 MHz (250 fs pulse duration). Changes in Fluo 5F fluorescence
were averaged from three trials and measured as DF/Fo.
Glutamate uncaging was achieved using a Verdi/Mira (Plotkin et al., 2014).
5 mM MNI-glutamate was superfused over the slice using a syringe pump
andmulti-barreled perfusionmanifold. Glutamate was uncaged adjacent to in-
dividual spines using 1 ms pulses of 720–725 nm light typically 10–20 mW in
power at the sample plane. uEPSC amplitudes were measured from averaged
(3–5 repetitions) traces.
Data Analysis and Statistics Methods
Data analysis was conducted with Igor Pro 6 and Clampfit 9. EPSP amplitude
was calculated from 50 sweeps immediately before the start of induction and
20–30 min after the end of induction. In studies describing optical or uncaging
responses measured from individual spines, the stated n indicates the number
of spines. Compiled data were expressed as mean ± SEM. Nonparametric
Mann-Whitney or Wilcoxon tests were used to assess the experiment results,
using a probability threshold of 0.05.
Statistical analyses for behavioral data were carried out using Prism 6. For
mice, data were analyzed using parametric repeated-measure two-way
ANOVA followed by post hoc Bonferroni’s test; for primates, data were
analyzed by Friedman’s nonparametric one-way ANOVA followed by post
hoc Dunn’s test.Neuron 88, 762–773, November 18, 2015 ª 2015 Elsevier Inc. 771
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